Evidence map›Paper›PMID 35871597›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Acquired von Willebrand Syndrome in a Patient with Multiple Comorbidities, Including MALT Lymphoma with IgA Monoclonal Gammopathy and Hyperviscosity Syndrome.

Mai Owari, Kayo Harada-Shirado, Ryuichi Togawa, Masahiko Fukatsu, Yuki Sato, Koichiro Fukuchi, Mamiko Endo, Hiroshi Takahashi, Satoshi Kimura, Tsukasa Osaki and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Autoimmune Diseases Affecting Hemostasis: A Narrative Review.International journal of molecular sciences · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Mai OwariDepartment of Hematology, Fukushima Medical University, Japan.
Kayo Harada-ShiradoDepartment of Hematology, Fukushima Medical University, Japan.
Ryuichi TogawaDepartment of Pulmonary Medicine, Fukushima Medical University, Japan.
Masahiko FukatsuDepartment of Hematology, Fukushima Medical University, Japan.
Yuki SatoDepartment of Hematology, Fukushima Medical University, Japan.
Koichiro FukuchiDepartment of Hematology, Fukushima Medical University, Japan.
Mamiko EndoDepartment of Hematology, Fukushima Medical University, Japan.
Hiroshi TakahashiDepartment of Hematology, Fukushima Medical University, Japan.
Satoshi KimuraDepartment of Hematology, Fukushima Medical University, Japan.
Tsukasa OsakiDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Japan.
Masayoshi SouriDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Japan.
Akitada IchinoseDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Japan.
Yoko ShibataDepartment of Pulmonary Medicine, Fukushima Medical University, Japan.
Yuko HashimotoDepartment of Diagnostic Pathology, Fukushima Medical University, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, Japan.
Fukushima Medical University · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired von Willebrand syndrome (aVWS) develops with various underlying diseases. We herein report an individual with aVWS associated with mucosa-associated lymphoid tissue lymphoma in the lungs complicated by hyperviscosity syndrome, Sjögren's syndrome, and hypothyroidism. This patient developed life-threatening hemorrhaging during a lung biopsy despite transfusion of concentrate of plasma-derived VWF/factor VIII. The use of rituximab caused remission of the lymphoma and hyperviscosity syndrome in parallel with the resolution of aVWS. Thus, lymphoma and hyperviscosity might result in aVWS. Invasive procedures with a risk of bleeding should be avoided in individuals with aVWS.

Indexed as

Lymphoma, B-Cell, Marginal ZoneParaproteinemiasvon Willebrand DiseasesHemorrhageHumansImmunoglobulin Avon Willebrand FactorImmunoglobulin Avon Willebrand Factoracquired von Willebrand syndromehyperviscosity syndromeMALT lymphomaSjögren's syndromevon Willebrand factor

Identifiers

PMID35871597
PMCPMC10017253
OpenAlexW4286542076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.